Trial Profile
Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 22 Dec 2015 New trial record